foxc1 sirna Search Results


92
OriGene sirna targeting foxc1
Fig. 1 Silencing and overexpression of <t>FOXC1</t> in pancreatic cancer cells. a Activity of FOXC1 transcription factor in IGF-1R-silenced HPAC cells. b Relative mRNA expression level of FOXC1 was assessed by real-time RT-PCR in IGF-1R-silenced HPAC cells. c Western blot analysis of IGF-1R and FOXC1 expression in IGF-1R-silenced HPAC cells. d Representative photographs of immunofluorescence analysis of FOXC1 expression in IGF-1R- silenced HPAC cells were visualized via confocal microscopy at × 60 magnification. e Representative qualitative (FOXC1-positive cells indicated by brown staining) and quantitative immunohistochemical analysis (bar diagram represents # of FOXC1-positive cells/field) of FOXC1 by tumor stage in human pancreatic ductal adenocarcinoma tissues and in normal pancreas tissue at × 40 magnification. IHC staining was quantitated at five random fields per section with at least 200 cells/field. f Western blot analysis of FOXC1 expression in a panel pancreatic cancer cell lines (HPAC, Capan-2, Capan-1, AsPC-1, PANC-1, MIA PaCa-2, and BxPC-3). g HPAC cells were transfected with three predesigned FOXC1 siRNAs (labeled as A, B, and C) at concentrations of 20, 40, and 60 nM along with scrambled control siRNA (Scr). Silencing efficacy of FOXC1 siRNA was determined using western blot analysis. h Representative photographs of immunofluorescence analysis of FOXC1 expression in FOXC1-silenced HPAC cells at × 60 magnification. i Relative mRNA expression level of FOXC1 was assessed by real-time PCR in FOXC1-silenced HPAC cells. j MIA PaCa-2 cells were transfected with FOXC1-overexpressing plasmid DNA from three different colonies (labeled as C1, C2, and C3) at concentrations of 1, 5, and 10 µg along with pCMV control plasmid DNA. Overexpression efficacy of FOXC1 plasmid DNA in MIA PaCa-2 cells was determined using western blotting. k Representative photographs of immunofluorescence analysis of FOXC1 expression in FOXC1-overexpressing MIA PaCa-2 cells at × 60 magnification. l Relative mRNA expression level of FOXC1 was assessed by real-time PCR in FOXC1-overexpressing MIA PaCa-2 cells. Data shown as mean ± SEM. Experiments (n = 3) were repeated three times in triplicates. *p < 0.05
Sirna Targeting Foxc1, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxc1+sirna/FOXC1+Human+siRNA+Oligo+Duplex/pm29976975-191-6-9
Average 92 stars, based on 1 article reviews
sirna targeting foxc1 - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology human foxc1 small
Correlation between clinicopathological features and expression of <t> FoxC1 </t> in patients with nasopharyngeal carcinoma.
Human Foxc1 Small, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxc1+sirna/FOXC1+siRNA/pmc04758279-67-1-18
Average 93 stars, based on 1 article reviews
human foxc1 small - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
Sangon Biotech foxc1 sirna
The mRNA expression level of CDC20 and <t>FOXC1</t> . a The mRNA expression level of FOXC1 . b The mRNA expression level of CDC20 . Sample size (n = 3). Data were expressed as mean ± SD. * indicates p value < 0.05 compared to control
Foxc1 Sirna, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxc1+sirna/sirnas+against+linc01614+and+foxc1/pmc08094490-32-10-17
Average 90 stars, based on 1 article reviews
foxc1 sirna - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Ribobio co foxc1 sirnas
The mRNA expression level of CDC20 and <t>FOXC1</t> . a The mRNA expression level of FOXC1 . b The mRNA expression level of CDC20 . Sample size (n = 3). Data were expressed as mean ± SD. * indicates p value < 0.05 compared to control
Foxc1 Sirnas, supplied by Ribobio co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxc1+sirna/foxc1+sirna/pm28591777-66-12-17
Average 90 stars, based on 1 article reviews
foxc1 sirnas - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

N/A
Foxc1 Mouse 3 unique 27mer siRNA duplexes 2 nmol each
  Buy from Supplier

Image Search Results


Fig. 1 Silencing and overexpression of FOXC1 in pancreatic cancer cells. a Activity of FOXC1 transcription factor in IGF-1R-silenced HPAC cells. b Relative mRNA expression level of FOXC1 was assessed by real-time RT-PCR in IGF-1R-silenced HPAC cells. c Western blot analysis of IGF-1R and FOXC1 expression in IGF-1R-silenced HPAC cells. d Representative photographs of immunofluorescence analysis of FOXC1 expression in IGF-1R- silenced HPAC cells were visualized via confocal microscopy at × 60 magnification. e Representative qualitative (FOXC1-positive cells indicated by brown staining) and quantitative immunohistochemical analysis (bar diagram represents # of FOXC1-positive cells/field) of FOXC1 by tumor stage in human pancreatic ductal adenocarcinoma tissues and in normal pancreas tissue at × 40 magnification. IHC staining was quantitated at five random fields per section with at least 200 cells/field. f Western blot analysis of FOXC1 expression in a panel pancreatic cancer cell lines (HPAC, Capan-2, Capan-1, AsPC-1, PANC-1, MIA PaCa-2, and BxPC-3). g HPAC cells were transfected with three predesigned FOXC1 siRNAs (labeled as A, B, and C) at concentrations of 20, 40, and 60 nM along with scrambled control siRNA (Scr). Silencing efficacy of FOXC1 siRNA was determined using western blot analysis. h Representative photographs of immunofluorescence analysis of FOXC1 expression in FOXC1-silenced HPAC cells at × 60 magnification. i Relative mRNA expression level of FOXC1 was assessed by real-time PCR in FOXC1-silenced HPAC cells. j MIA PaCa-2 cells were transfected with FOXC1-overexpressing plasmid DNA from three different colonies (labeled as C1, C2, and C3) at concentrations of 1, 5, and 10 µg along with pCMV control plasmid DNA. Overexpression efficacy of FOXC1 plasmid DNA in MIA PaCa-2 cells was determined using western blotting. k Representative photographs of immunofluorescence analysis of FOXC1 expression in FOXC1-overexpressing MIA PaCa-2 cells at × 60 magnification. l Relative mRNA expression level of FOXC1 was assessed by real-time PCR in FOXC1-overexpressing MIA PaCa-2 cells. Data shown as mean ± SEM. Experiments (n = 3) were repeated three times in triplicates. *p < 0.05

Journal: Oncogenesis

Article Title: FOXC1 plays a crucial role in the growth of pancreatic cancer.

doi: 10.1038/s41389-018-0061-7

Figure Lengend Snippet: Fig. 1 Silencing and overexpression of FOXC1 in pancreatic cancer cells. a Activity of FOXC1 transcription factor in IGF-1R-silenced HPAC cells. b Relative mRNA expression level of FOXC1 was assessed by real-time RT-PCR in IGF-1R-silenced HPAC cells. c Western blot analysis of IGF-1R and FOXC1 expression in IGF-1R-silenced HPAC cells. d Representative photographs of immunofluorescence analysis of FOXC1 expression in IGF-1R- silenced HPAC cells were visualized via confocal microscopy at × 60 magnification. e Representative qualitative (FOXC1-positive cells indicated by brown staining) and quantitative immunohistochemical analysis (bar diagram represents # of FOXC1-positive cells/field) of FOXC1 by tumor stage in human pancreatic ductal adenocarcinoma tissues and in normal pancreas tissue at × 40 magnification. IHC staining was quantitated at five random fields per section with at least 200 cells/field. f Western blot analysis of FOXC1 expression in a panel pancreatic cancer cell lines (HPAC, Capan-2, Capan-1, AsPC-1, PANC-1, MIA PaCa-2, and BxPC-3). g HPAC cells were transfected with three predesigned FOXC1 siRNAs (labeled as A, B, and C) at concentrations of 20, 40, and 60 nM along with scrambled control siRNA (Scr). Silencing efficacy of FOXC1 siRNA was determined using western blot analysis. h Representative photographs of immunofluorescence analysis of FOXC1 expression in FOXC1-silenced HPAC cells at × 60 magnification. i Relative mRNA expression level of FOXC1 was assessed by real-time PCR in FOXC1-silenced HPAC cells. j MIA PaCa-2 cells were transfected with FOXC1-overexpressing plasmid DNA from three different colonies (labeled as C1, C2, and C3) at concentrations of 1, 5, and 10 µg along with pCMV control plasmid DNA. Overexpression efficacy of FOXC1 plasmid DNA in MIA PaCa-2 cells was determined using western blotting. k Representative photographs of immunofluorescence analysis of FOXC1 expression in FOXC1-overexpressing MIA PaCa-2 cells at × 60 magnification. l Relative mRNA expression level of FOXC1 was assessed by real-time PCR in FOXC1-overexpressing MIA PaCa-2 cells. Data shown as mean ± SEM. Experiments (n = 3) were repeated three times in triplicates. *p < 0.05

Article Snippet: Further, FOXC1 expression was silenced using siRNA targeting FOXC1 (Origene, Rockville, MD, USA).

Techniques: Over Expression, Activity Assay, Expressing, Quantitative RT-PCR, Western Blot, Confocal Microscopy, Staining, Immunohistochemical staining, Immunohistochemistry, Transfection, Labeling, Control, Real-time Polymerase Chain Reaction, Plasmid Preparation

Fig. 2 Crosstalk between FOXC1 and IGF-1R in pancreatic cancer cells. a Western blot analysis of FOXC1 and IGF-1R expression in FOXC1- silenced HPAC cells. b Immunofluorescence analysis of IGF-1R expression in FOXC1-silenced HPAC cells visualized through confocal microscopy at × 60 magnification. c Western blot analysis of FOXC1 and IGF-1R expression in FOXC1-overexpressing MIA PaCa-2 cells. d Immunofluorescence analysis showed increased IGF-1R expression in FOXC1-overexpressing MIA PaCa-2 cells (× 60 magnification). e Western blot analysis of FOXC1 and IGF-1R expression in HPAC cells treated with scramble siRNA (Scr) or IGF-1R siRNA or IGF-1R siRNA plus 100 nM of IGF-1 or 100 nM of IGF-1 alone. f MTS assay was used to measure the cell proliferation in response to IGF-1 treatment (5, 50, 100, and 200 nM) in parental and FOXC1-silenced HPAC cells. g Western blot analysis of IGF-1R, FOXC1, pAKT, Cyclin D1, and Vimentin in HPAC cells treated with FOXC1 siRNA or IGF-1 or FOXC1 siRNA plus IGF-1. h Western blot analysis of FOXC1 and IGF-1R expression in parental and FOXC1-overexpressing MIA PaCa-2 cells treated with or without Picropodophyllin (PPP). i Gaussia luciferase assay was used to show FOXC1 promoter activity in MIA PaCa-2 cells in the presence of IGF-1 or PPP. Data shown as mean ± SEM. Experiments (n = 3) were repeated three times in triplicates. *p < 0.05

Journal: Oncogenesis

Article Title: FOXC1 plays a crucial role in the growth of pancreatic cancer.

doi: 10.1038/s41389-018-0061-7

Figure Lengend Snippet: Fig. 2 Crosstalk between FOXC1 and IGF-1R in pancreatic cancer cells. a Western blot analysis of FOXC1 and IGF-1R expression in FOXC1- silenced HPAC cells. b Immunofluorescence analysis of IGF-1R expression in FOXC1-silenced HPAC cells visualized through confocal microscopy at × 60 magnification. c Western blot analysis of FOXC1 and IGF-1R expression in FOXC1-overexpressing MIA PaCa-2 cells. d Immunofluorescence analysis showed increased IGF-1R expression in FOXC1-overexpressing MIA PaCa-2 cells (× 60 magnification). e Western blot analysis of FOXC1 and IGF-1R expression in HPAC cells treated with scramble siRNA (Scr) or IGF-1R siRNA or IGF-1R siRNA plus 100 nM of IGF-1 or 100 nM of IGF-1 alone. f MTS assay was used to measure the cell proliferation in response to IGF-1 treatment (5, 50, 100, and 200 nM) in parental and FOXC1-silenced HPAC cells. g Western blot analysis of IGF-1R, FOXC1, pAKT, Cyclin D1, and Vimentin in HPAC cells treated with FOXC1 siRNA or IGF-1 or FOXC1 siRNA plus IGF-1. h Western blot analysis of FOXC1 and IGF-1R expression in parental and FOXC1-overexpressing MIA PaCa-2 cells treated with or without Picropodophyllin (PPP). i Gaussia luciferase assay was used to show FOXC1 promoter activity in MIA PaCa-2 cells in the presence of IGF-1 or PPP. Data shown as mean ± SEM. Experiments (n = 3) were repeated three times in triplicates. *p < 0.05

Article Snippet: Further, FOXC1 expression was silenced using siRNA targeting FOXC1 (Origene, Rockville, MD, USA).

Techniques: Western Blot, Expressing, Confocal Microscopy, MTS Assay, Luciferase, Activity Assay

Fig. 3 Effect of FOXC1 on pancreatic cancer cell proliferation. a Morphological changes occurred in FOXC1-silenced HPAC cells, which were observed under a light microscope at × 10 magnification. b MTS assay was used to measure cell proliferation of FOXC1-silenced HPAC cells. c Western blot analysis of proliferation markers in FOXC1-silenced HPAC cells. d Morphological changes occurred in FOXC1-overexpressing MIA PaCa-2 cells, which were observed under a light microscope at × 10 magnification. e MTS assay was used to measure the proliferation of FOXC1- overexpressing MIA PaCa-2 cells. f Western blot analysis of proliferation markers in FOXC1-overexpressing MIA PaCa-2 cells. Results represented as mean ± SEM. Data shown as mean ± SEM. Experiments (n = 3) were repeated three times in triplicates. *p < 0.05

Journal: Oncogenesis

Article Title: FOXC1 plays a crucial role in the growth of pancreatic cancer.

doi: 10.1038/s41389-018-0061-7

Figure Lengend Snippet: Fig. 3 Effect of FOXC1 on pancreatic cancer cell proliferation. a Morphological changes occurred in FOXC1-silenced HPAC cells, which were observed under a light microscope at × 10 magnification. b MTS assay was used to measure cell proliferation of FOXC1-silenced HPAC cells. c Western blot analysis of proliferation markers in FOXC1-silenced HPAC cells. d Morphological changes occurred in FOXC1-overexpressing MIA PaCa-2 cells, which were observed under a light microscope at × 10 magnification. e MTS assay was used to measure the proliferation of FOXC1- overexpressing MIA PaCa-2 cells. f Western blot analysis of proliferation markers in FOXC1-overexpressing MIA PaCa-2 cells. Results represented as mean ± SEM. Data shown as mean ± SEM. Experiments (n = 3) were repeated three times in triplicates. *p < 0.05

Article Snippet: Further, FOXC1 expression was silenced using siRNA targeting FOXC1 (Origene, Rockville, MD, USA).

Techniques: Light Microscopy, MTS Assay, Western Blot

Fig. 4 Effect of FOXC1 on metastasis of pancreatic cancer cells. a Wound-healing assay was performed in control (Scr) and FOXC1-silenced (siFOXC1) HPAC cells; migration was analyzed using an automated Nikon Biostation CT at 2 h intervals for up to 96 h at × 4 magnification. b Quantitative analysis of migration in FOXC1-silenced HPAC cells was calculated using NIS-Element AR software. c Wound-healing assay was performed in control (empty vector) and FOXC1-overexpressing (OE FOXC1) MIA PaCa-2 cells; migration was analyzed using an automated Nikon Biostation CT at 2 h intervals for up to 96 h at × 4 magnification. d Quantitative analysis of migration in FOXC1-overexpressing MIA PaCa-2 was calculated using NIS-Element AR software. e Invasiveness of FOXC1-silenced HPAC cells was observed using a Matrigel invasion assay (left: × 20 magnification; right: × 100 magnification). f Percentage invasion of control (Scr) and FOXC1-silenced (siFOXC1) HPAC cells was obtained by counting invaded cells from each group. g Invasiveness of FOXC1-overexpressing MIA PaCa-2 cells was observed using a Matrigel invasion assay (left: × 20 magnification; right: × 100 magnification). h Percentage invasion of control (pCMV) and FOXC1-overexpressing (OE FOXC1) MIA PaCa-2 cells was obtained by counting invaded cells from each group. i Colony formation assay was performed with control (Scr) and FOXC1-silenced (siFOXC1) HPAC cells (left: × 20 magnification; right: × 100 magnification). j The percentage of colonies were calculated with parental HPAC control cells serving as the baseline. k Colony formation assay was performed with control (pCMV) and FOXC1-overexpressing (OE FOXC1) MIA PaCa-2 cells (left: × 20 magnification; right: × 100 magnification). l The percentage of colonies were calculated with parental MIA PaCa-2 control cells serving as the baseline. m Western blot analysis of EMT markers in FOXC1-silenced HPAC cells and n FOXC1-overexpressing MIA PaCa-2 cells. Data shown as mean ± SEM. Experiments (n = 3) were repeated three times in triplicates. *p < 0.05

Journal: Oncogenesis

Article Title: FOXC1 plays a crucial role in the growth of pancreatic cancer.

doi: 10.1038/s41389-018-0061-7

Figure Lengend Snippet: Fig. 4 Effect of FOXC1 on metastasis of pancreatic cancer cells. a Wound-healing assay was performed in control (Scr) and FOXC1-silenced (siFOXC1) HPAC cells; migration was analyzed using an automated Nikon Biostation CT at 2 h intervals for up to 96 h at × 4 magnification. b Quantitative analysis of migration in FOXC1-silenced HPAC cells was calculated using NIS-Element AR software. c Wound-healing assay was performed in control (empty vector) and FOXC1-overexpressing (OE FOXC1) MIA PaCa-2 cells; migration was analyzed using an automated Nikon Biostation CT at 2 h intervals for up to 96 h at × 4 magnification. d Quantitative analysis of migration in FOXC1-overexpressing MIA PaCa-2 was calculated using NIS-Element AR software. e Invasiveness of FOXC1-silenced HPAC cells was observed using a Matrigel invasion assay (left: × 20 magnification; right: × 100 magnification). f Percentage invasion of control (Scr) and FOXC1-silenced (siFOXC1) HPAC cells was obtained by counting invaded cells from each group. g Invasiveness of FOXC1-overexpressing MIA PaCa-2 cells was observed using a Matrigel invasion assay (left: × 20 magnification; right: × 100 magnification). h Percentage invasion of control (pCMV) and FOXC1-overexpressing (OE FOXC1) MIA PaCa-2 cells was obtained by counting invaded cells from each group. i Colony formation assay was performed with control (Scr) and FOXC1-silenced (siFOXC1) HPAC cells (left: × 20 magnification; right: × 100 magnification). j The percentage of colonies were calculated with parental HPAC control cells serving as the baseline. k Colony formation assay was performed with control (pCMV) and FOXC1-overexpressing (OE FOXC1) MIA PaCa-2 cells (left: × 20 magnification; right: × 100 magnification). l The percentage of colonies were calculated with parental MIA PaCa-2 control cells serving as the baseline. m Western blot analysis of EMT markers in FOXC1-silenced HPAC cells and n FOXC1-overexpressing MIA PaCa-2 cells. Data shown as mean ± SEM. Experiments (n = 3) were repeated three times in triplicates. *p < 0.05

Article Snippet: Further, FOXC1 expression was silenced using siRNA targeting FOXC1 (Origene, Rockville, MD, USA).

Techniques: Wound Healing Assay, Control, Migration, Software, Plasmid Preparation, Invasion Assay, Colony Assay, Western Blot

Fig. 5 Effect of FOXC1 on in vivo tumor growth. a The tumor growth curve of FOXC1-silenced HPAC xenografts. b Representative photographs of mice subcutaneously injected with parental or siFOXC1-silenced HPAC cells. c Representative photographs of HPAC xenograft tumors excised from the nude mice. d Western blot analysis of FOXC1 protein expression in HPAC xenograft tumors. e Body weight of HPAC xenografted nude mice. f The tumor growth curve of FOXC1-overexpressing MIA PaCa-2 xenografts. g Representative photographs of mice subcutaneously injected with parental or FOXC1-overexpressing MIA PaCa-2 cells. h Representative photographs of MIA PaCa-2 xenograft tumors excised from the nude mice. i Western blot analysis of FOXC1 protein expression in MIA PaCa-2 xenograft. j Body weight of MIA PaCa-2-xenografted nude mice. Data shown as mean ± SEM. Experiments (n = 6 mice/group) were repeated three times. *p < 0.05

Journal: Oncogenesis

Article Title: FOXC1 plays a crucial role in the growth of pancreatic cancer.

doi: 10.1038/s41389-018-0061-7

Figure Lengend Snippet: Fig. 5 Effect of FOXC1 on in vivo tumor growth. a The tumor growth curve of FOXC1-silenced HPAC xenografts. b Representative photographs of mice subcutaneously injected with parental or siFOXC1-silenced HPAC cells. c Representative photographs of HPAC xenograft tumors excised from the nude mice. d Western blot analysis of FOXC1 protein expression in HPAC xenograft tumors. e Body weight of HPAC xenografted nude mice. f The tumor growth curve of FOXC1-overexpressing MIA PaCa-2 xenografts. g Representative photographs of mice subcutaneously injected with parental or FOXC1-overexpressing MIA PaCa-2 cells. h Representative photographs of MIA PaCa-2 xenograft tumors excised from the nude mice. i Western blot analysis of FOXC1 protein expression in MIA PaCa-2 xenograft. j Body weight of MIA PaCa-2-xenografted nude mice. Data shown as mean ± SEM. Experiments (n = 6 mice/group) were repeated three times. *p < 0.05

Article Snippet: Further, FOXC1 expression was silenced using siRNA targeting FOXC1 (Origene, Rockville, MD, USA).

Techniques: In Vivo, Injection, Western Blot, Expressing

Fig. 6 Effect of FOXC1 on proliferation and EMT of xenograft tumors. a Western blot analysis of proliferation markers in FOXC1-silenced HPAC xenograft tumors and b FOXC1-overexpressing MIA PaCa-2 xenograft tumors. c Western blot analysis of EMT markers in FOXC1-silenced HPAC xenograft tumors and d FOXC1-overexpressing MIA PaCa-2 xenograft tumors. e Immunohistochemical analysis of Ki67, Gli1, and VEGFR2 in FOXC1- silenced HPAC xenograft tumors and f FOXC1-overexpressing MIA PaCa-2 xenograft tumors. Data shown as mean ± SEM. Experiments (n = 3) were repeated three times. *p < 0.05

Journal: Oncogenesis

Article Title: FOXC1 plays a crucial role in the growth of pancreatic cancer.

doi: 10.1038/s41389-018-0061-7

Figure Lengend Snippet: Fig. 6 Effect of FOXC1 on proliferation and EMT of xenograft tumors. a Western blot analysis of proliferation markers in FOXC1-silenced HPAC xenograft tumors and b FOXC1-overexpressing MIA PaCa-2 xenograft tumors. c Western blot analysis of EMT markers in FOXC1-silenced HPAC xenograft tumors and d FOXC1-overexpressing MIA PaCa-2 xenograft tumors. e Immunohistochemical analysis of Ki67, Gli1, and VEGFR2 in FOXC1- silenced HPAC xenograft tumors and f FOXC1-overexpressing MIA PaCa-2 xenograft tumors. Data shown as mean ± SEM. Experiments (n = 3) were repeated three times. *p < 0.05

Article Snippet: Further, FOXC1 expression was silenced using siRNA targeting FOXC1 (Origene, Rockville, MD, USA).

Techniques: Western Blot, Immunohistochemical staining

Correlation between clinicopathological features and expression of  FoxC1  in patients with nasopharyngeal carcinoma.

Journal: Molecular Medicine Reports

Article Title: Forkhead box C1 induces epithelial-mesenchymal transition and is a potential therapeutic target in nasopharyngeal carcinoma

doi: 10.3892/mmr.2015.4427

Figure Lengend Snippet: Correlation between clinicopathological features and expression of FoxC1 in patients with nasopharyngeal carcinoma.

Article Snippet: The human FoxC1 small interfering (si)RNA (cat. no. sc-43766) and control siRNA-A (cat. no. sc-37007) were purchased from Santa Cruz Biotechnology, Inc. At 24 h prior to transfection, CNE2 cells were plated at a density of 5×10 4 cells/well in a six-well plate.

Techniques: Expressing

FoxC1 expression in NPC tissues and cell lines. (A) Immunohistochemical analysis of FoxC1 showing upregulation in NPC compared with that in chronically inflamed nasopharyngeal tissues (magnification, ×100; scale bar, 50 µm). (B) Western blot analysis showing elevated FoxC1 protein levels in NPC lines than in the immortalized nasopharyngeal epithelial cell line NP69. Values are expressed as the mean ± standard deviation. ** P<0.01. Fox, forkhead box; NPC, nasopharyngeal carcinoma.

Journal: Molecular Medicine Reports

Article Title: Forkhead box C1 induces epithelial-mesenchymal transition and is a potential therapeutic target in nasopharyngeal carcinoma

doi: 10.3892/mmr.2015.4427

Figure Lengend Snippet: FoxC1 expression in NPC tissues and cell lines. (A) Immunohistochemical analysis of FoxC1 showing upregulation in NPC compared with that in chronically inflamed nasopharyngeal tissues (magnification, ×100; scale bar, 50 µm). (B) Western blot analysis showing elevated FoxC1 protein levels in NPC lines than in the immortalized nasopharyngeal epithelial cell line NP69. Values are expressed as the mean ± standard deviation. ** P<0.01. Fox, forkhead box; NPC, nasopharyngeal carcinoma.

Article Snippet: The human FoxC1 small interfering (si)RNA (cat. no. sc-43766) and control siRNA-A (cat. no. sc-37007) were purchased from Santa Cruz Biotechnology, Inc. At 24 h prior to transfection, CNE2 cells were plated at a density of 5×10 4 cells/well in a six-well plate.

Techniques: Expressing, Immunohistochemical staining, Western Blot, Standard Deviation

High FoxC1 expression is associated with mesenchymal and epithelial markers in nasopharyngeal carcinoma. (A) Immunohistochemical staining of FoxC1 protein and mesenchymal and epithelial markers, including vimentin, fibronectin, N-cadherin, E-cadherin and β-catenin in nasopharyngeal carcinoma. In case 1, FoxC1 expression was low and the cancer cells were negative for vimentin, fibronectin and N-cadherin expression, while being highly positive for E-cadherin and β-catenin expression. In case 2, FoxC1 expression was high and tissue stained positive for vimentin, fibronectin, N-cadherin, E-cadherin and β-catenin. (B) According to statistical analysis, FoxC1 expression was positively correlated with vimentin, fibronectin and N-cadherin expression, but not with E-cadherin and β-catenin expression. Values are expressed as the mean ± standard deviation. Fox, forkhead box.

Journal: Molecular Medicine Reports

Article Title: Forkhead box C1 induces epithelial-mesenchymal transition and is a potential therapeutic target in nasopharyngeal carcinoma

doi: 10.3892/mmr.2015.4427

Figure Lengend Snippet: High FoxC1 expression is associated with mesenchymal and epithelial markers in nasopharyngeal carcinoma. (A) Immunohistochemical staining of FoxC1 protein and mesenchymal and epithelial markers, including vimentin, fibronectin, N-cadherin, E-cadherin and β-catenin in nasopharyngeal carcinoma. In case 1, FoxC1 expression was low and the cancer cells were negative for vimentin, fibronectin and N-cadherin expression, while being highly positive for E-cadherin and β-catenin expression. In case 2, FoxC1 expression was high and tissue stained positive for vimentin, fibronectin, N-cadherin, E-cadherin and β-catenin. (B) According to statistical analysis, FoxC1 expression was positively correlated with vimentin, fibronectin and N-cadherin expression, but not with E-cadherin and β-catenin expression. Values are expressed as the mean ± standard deviation. Fox, forkhead box.

Article Snippet: The human FoxC1 small interfering (si)RNA (cat. no. sc-43766) and control siRNA-A (cat. no. sc-37007) were purchased from Santa Cruz Biotechnology, Inc. At 24 h prior to transfection, CNE2 cells were plated at a density of 5×10 4 cells/well in a six-well plate.

Techniques: Expressing, Immunohistochemical staining, Staining, Standard Deviation

Mesenchymal and epithelial marker expression after FoxC1 knockdown by siRNA in CNE2 cells. Western blot analysis showed that vimentin, fibronectin and N-cadherin, but not E-cadherin and β-catenin were downregulated in CNE2 cells after FoxC1 knockdown. Values are expressed as the mean ± standard deviation. ** P<0.01. Fox, forkhead box; siRNA, small interfering RNA; NC, negative control.

Journal: Molecular Medicine Reports

Article Title: Forkhead box C1 induces epithelial-mesenchymal transition and is a potential therapeutic target in nasopharyngeal carcinoma

doi: 10.3892/mmr.2015.4427

Figure Lengend Snippet: Mesenchymal and epithelial marker expression after FoxC1 knockdown by siRNA in CNE2 cells. Western blot analysis showed that vimentin, fibronectin and N-cadherin, but not E-cadherin and β-catenin were downregulated in CNE2 cells after FoxC1 knockdown. Values are expressed as the mean ± standard deviation. ** P<0.01. Fox, forkhead box; siRNA, small interfering RNA; NC, negative control.

Article Snippet: The human FoxC1 small interfering (si)RNA (cat. no. sc-43766) and control siRNA-A (cat. no. sc-37007) were purchased from Santa Cruz Biotechnology, Inc. At 24 h prior to transfection, CNE2 cells were plated at a density of 5×10 4 cells/well in a six-well plate.

Techniques: Marker, Expressing, Knockdown, Western Blot, Standard Deviation, Small Interfering RNA, Negative Control

FoxC1 knockdown by siRNA decreases the migrative and invasive ability of CNE2 cells in vitro . (A) Giemsa staining showed that the number of migrated and invaded cells was markedly decreased following FoxC1 knockdown. (B) Wound healing assay showing that knockdown of FoxC1 by siRNA reduced the distance of migration of CNE2 cells. Values are expressed as the mean ± standard deviation. ** P<0.01. Fox, forkhead box; NC, negative control; siRNA, small interfering RNA.

Journal: Molecular Medicine Reports

Article Title: Forkhead box C1 induces epithelial-mesenchymal transition and is a potential therapeutic target in nasopharyngeal carcinoma

doi: 10.3892/mmr.2015.4427

Figure Lengend Snippet: FoxC1 knockdown by siRNA decreases the migrative and invasive ability of CNE2 cells in vitro . (A) Giemsa staining showed that the number of migrated and invaded cells was markedly decreased following FoxC1 knockdown. (B) Wound healing assay showing that knockdown of FoxC1 by siRNA reduced the distance of migration of CNE2 cells. Values are expressed as the mean ± standard deviation. ** P<0.01. Fox, forkhead box; NC, negative control; siRNA, small interfering RNA.

Article Snippet: The human FoxC1 small interfering (si)RNA (cat. no. sc-43766) and control siRNA-A (cat. no. sc-37007) were purchased from Santa Cruz Biotechnology, Inc. At 24 h prior to transfection, CNE2 cells were plated at a density of 5×10 4 cells/well in a six-well plate.

Techniques: Knockdown, In Vitro, Staining, Wound Healing Assay, Migration, Standard Deviation, Negative Control, Small Interfering RNA

The mRNA expression level of CDC20 and FOXC1 . a The mRNA expression level of FOXC1 . b The mRNA expression level of CDC20 . Sample size (n = 3). Data were expressed as mean ± SD. * indicates p value < 0.05 compared to control

Journal: BMC Medical Genomics

Article Title: Bioinformatic identification of hub genes and related transcription factors in low shear stress treated endothelial cells

doi: 10.1186/s12920-021-00971-6

Figure Lengend Snippet: The mRNA expression level of CDC20 and FOXC1 . a The mRNA expression level of FOXC1 . b The mRNA expression level of CDC20 . Sample size (n = 3). Data were expressed as mean ± SD. * indicates p value < 0.05 compared to control

Article Snippet: When the density reached 70–80%, ECs were transiently transfected with FOXC1 siRNA or scrambled control supplied by Sangon Biotech (Biotech (Shanghai) Co., Ltd. Shanghai, China) at the concentration of 100 nM to down-regulate the expression of FOXC1 .

Techniques: Expressing, Control